Inflammatix, Inc.
Burlingame, California, 94010, United States
NCT Number: NCT03606382
This study will analyze gene expression data from various biological specimens collected from voluntary participants.
Looking for future studies?
Notify Me1 year and older
All sexes
Observational
Burlingame, California, 94010, United States
Primary objective is the collection of specimens from volunteers for the development and validation of HostDx tests. The study does only encompass specimen collection - Therefore, no traditional endpoint is defined but rather the successful collection of clinical specimens is defined as the endpoint.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HostDx Fever test to distinguish between viral and bacterial infections
HostDx Fever test to determine the severity of a presented, suspected infection.
Time frame: 1 Day
Blood collection, upper respiratory specimens including. nasal swabs, nasal washes, nasopharyngeal swabs, buccal swabs, buccal washes), sputum, saliva, urine and a skin/soft-tissue specimen (dermal).
Inflammatix
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04255303
Acute Respiratory Infection
New York, United States
View Trial DetailsNCT06981130
Acute Respiratory Infection
Merthyr Tydfil, Rhondda Cynon Taff, United Kingdom
View Trial DetailsNCT06183229
Acute Respiratory Infection, Infections
Saint Petersburg, Russia
View Trial DetailsNCT04844541
Acute Respiratory Infection, COVID-19
Baltimore, Maryland, United States
View Trial Details